NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
The brokerage firm Motilal Oswal has raised its earnings estimates for Zydus Lifesciences Ltd. by 5%/4% for FY27/FY28, factoring in-
- increased traction in limited-competition products in the US,
- industry-beating performance in domestic formulation and other emerging markets,
- higher R&D spending, and
- enhanced efforts toward marketing/promotion.
The brokerage values Zydus Lifesciences at 21x 12- month forward earnings to arrive at a target price of Rs 1,080.
Considering a higher base of FY26, Motilal Oswal expect 7% earnings CAGR over FY26-28. The current valuation provides limited upside and hence, the brokerage maintains Neutral rating on the stock.
Click on the attachment to read the full report:
ALSO READ: Indraprastha Gas Shares In Focus As Systematix Revises Target Price After Q4 Results — Check Upside
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
